MRC1 and neoplasm: This concretely showed case that primarily DDR-related oncogenic processes (here increased mutability and antigenicity resulting from MMR defects) can be therapeutically targeted solely using immunotherapy, with profound and prolonged efficacy in patients whatever the tumour type [5–8].